TTK HEALTHCARE LTD.-$

TTK Healthcare Ltd announced the outcome of its Board Meeting, wherein the Unaudited Financial Results for the First Quarter ended June 30, 2026, were approved. The results were reviewed by the Audit Committee and subsequently approved by the Board of Directors. The meeting commenced at 12 noon and concluded at 1:00 p.m. The company also provided a limited review report from its statutory auditors.

TTK Healthcare's standalone revenue came in at ₹257.56 Cr, up 13.7% YoY and 18.2% QoQ, with PAT of ₹21.28 Cr, up 63.7% YoY but down 2.2% QoQ. Basic EPS was ₹15.06, against ₹9.20 a year ago and ₹15.40 last quarter. The company carries no subsidiaries, so standalone is the sole basis for these results. The headline YoY PAT jump is materially inflated by a one-off: Note 3 discloses the company invoiced ₹7.02 Cr (₹701.85 lakh) of USAID export orders against Protective Devices inventory that had been fully written off in FY25, meaning near the entire amount drops to pre-tax profit. Stripping this out at the quarter's 26.3% effective tax rate, adjusted PAT growth is ~24% YoY versus 13.7% revenue growth — still profit outgrowing revenue, but far short of the 64% reported figure. Net margin improved to 7.76% from 5.32% YoY (though it compressed from 9.23% in Q4FY26), while operating margin rose to 5.72% from a depressed 1.18% a year ago. The Protective Devices segment was the swing factor, moving to a ₹6.13 Cr segment profit from a ₹5.44 Cr loss in Q1FY26 — the single largest driver of the YoY improvement, substantially aided by the one-off order. Animal Welfare segment profit, by contrast, fell to ₹1.15 Cr from ₹2.34 Cr YoY despite segment revenue growth, partially offsetting the Protective Devices strength. No formal Street consensus estimates or management guidance for this quarter were found on record or via web search — TTK Healthcare is thinly covered as a small-cap, so vsStreet and vsGuidance are marked unknown/none rather than assumed. The management press release furnished only the standard Regulation 30 board-outcome disclosure with no forward commentary to grade against. Separately, on July 23, 2026 the company signed a definitive agreement to sell its EVA and Good Home brands (Consumer Products segment) to Wipro Enterprises for ₹256 Cr against a net book value of just ₹0.70 Cr; the deal is expected to close by September 30, 2026 and its gain is not reflected in this quarter's numbers. Going into Q2 FY27, the key markers are whether Protective Devices holds its profitability without the one-off inventory recovery, and whether the EVA/Good Home divestment gain shows up once that transaction completes.

TTK Healthcare Ltd has announced that its Board of Directors will convene on August 6, 2026, to consider and approve the Unaudited Financial Results for the First Quarter ended June 30, 2026. Concurrently, the company has confirmed that the trading window for designated persons and their immediate relatives will remain closed from July 1, 2026, to August 8, 2026, in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

TTK Healthcare Ltd held its 68th Annual General Meeting on July 24, 2026. The Chairman's speech highlighted a 7% revenue growth to ₹857.28 crores for FY 2025-26, though pre-tax profit declined to ₹82.56 crores from ₹108.33 crores due to exceptional items and lower profit from the Protective Devices Division. The company holds a free cash balance of ₹900 crores. A significant development is the divestment of the EVA and Good Home brands to Wipro Enterprises Private Limited for ₹256 crores plus GST. The Consumer Products Business saw static performance with efforts to strengthen Woodward's Gripe Water and expand its 'Care' segment. Skore brand showed resilient performance with 6% value growth.

TTK Healthcare Ltd announced the sale of its 'EVA' and 'Good Home' brands to Wipro Enterprises Private Limited for ₹256 crores plus applicable GST. The transaction, approved by the Board of Directors, is expected to be completed by September 30, 2026, subject to customary conditions precedent. The brands contributed approximately ₹148 crores, or 17% of the company's total turnover in FY 2025-26. The buyer is not part of the promoter group, and the transaction is not considered a related party transaction or a slump sale.

TTK Healthcare Ltd announced the sale of its 'EVA' and 'Good Home' brands to M/s Wipro Enterprises Private Limited for ₹256 crores plus applicable GST. The definitive agreements have been executed, with the transaction closing expected by September 30, 2026, subject to customary conditions precedent. The brands contributed approximately ₹148 crores, representing 17% of the company's total turnover for FY 2025-26. This transaction is not considered a related party transaction or a slump sale.

TTK Healthcare Ltd. has announced its 68th Annual General Meeting (AGM) scheduled for Friday, July 24, 2026, at 12:00 noon. The meeting will be conducted via Video Conferencing/Other Audio Visual Means (VC/OAVM) in compliance with MCA circulars and relevant laws. The company has also submitted the soft copy of its Annual Report for the Financial Year 2025-26 and the Notice of the 68th AGM, as per Regulation 34(1) of SEBI (LODR) Regulations, 2015. Both documents have been sent to shareholders electronically and are available on the company's website. The report includes financial highlights, board of directors' details, company secretary, registered office, factories, bankers, auditors, and registrar details.

TTK Healthcare Ltd has announced its 68th Annual General Meeting (AGM) will be held on Friday, July 24, 2026, at 12:00 noon via Video Conferencing/Other Audio Visual Means (VC/OAVM). The company has filed its Annual Report for the Financial Year 2025-26, in compliance with SEBI (LODR) Regulations, 2015. The report and the notice of the AGM have been sent to shareholders electronically and are also available on the company's website. The filing includes details of the Board of Directors, Company Secretary, registered office, factories, depots, bankers, and auditors. Financial highlights for FY2025-26 are presented alongside previous years, showing revenue from continuing operations.

TTK Healthcare Ltd has released its Annual Report for the Financial Year 2025-26, along with the notice for its 68th Annual General Meeting (AGM). The AGM is scheduled for July 24, 2026, at 12:00 noon, to be conducted via Video Conferencing/Other Audio Visual Means (VC/OAVM). The report, submitted as per SEBI (LODR) Regulations, 2015, includes financial highlights, board's report, corporate governance, and sustainability reports. The company has also uploaded the Annual Report and AGM notice on its website and sent them to shareholders electronically. The financial highlights indicate Revenue from Operations and Other Income for FY 2025-26 was ₹87,274.83 lakhs.

TTK Healthcare Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, adhering to SEBI regulations. The report details the company's commitment to sustainable growth, aligning its operations with customer needs while minimizing environmental and social impacts. It covers general disclosures including corporate identity, registered office, financial year, stock exchange listings, paid-up capital, and contact details for BRSR queries. The company's business activities encompass the manufacture and distribution of Consumer, Animal Welfare, and Food Products, along with Medical and Protective Devices. The report also outlines operational details, market reach across 28 states and 8 union territories in India, and international presence in 28 countries, with exports contributing 6.41% to turnover. Customer base includes direct consumers, distributors, healthcare professionals, and institutional clients.